Form ADV disclosures

Healthcare and life sciences investment advisers face a specific disclosure burden under Form ADV that most pure-play financial firms do not: the U.S. Securities and Exchange Commission has signaled, through its 2023 Marketing Rule examination priorities and its Staff Risk Alert on adviser due diligence practices, that healthcare-focused advisers must document material conflicts arising from portfolio company clinical relationships, licensing dependencies, and government reimbursement exposure. The Financial Industry Regulatory Authority applies parallel scrutiny where dual-registered entities are involved. Compliance teams at life sciences advisers are currently reconciling Part 2A narrative disclosures against updated conflict-of-interest inventories before their next annual amendment cycle.